Filing Flows › Bioadaptives (BDPT) › Q3 2025
Bioadaptives (BDPT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Bioadaptives (BDPT) reported revenue of $5K for the third quarter 2025 (Q3 2025) and +44% from the quarter before.
Bioadaptives, Q3 2025: revenue $5K, net loss $380K, operating cash flow −$151K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | +44% | — |
| Operating profit | −$266K | — | — |
| Net earnings | −$380K | — | — |
| Operating cash flow | −$151K | — | — |
What changed
Revenue was $5K in Q3 2025, up 44% from the previous quarter.
Gross margin was 83.1%. Operating costs exceeded revenue by $266K, an operating margin of -5735.9%. The quarter ended with a net loss of $380K, narrower than the previous quarter's $552K loss.
Operating cash flow was −$151K. Non-cash charges added back $2K of depreciation and amortization. Working capital and other items added $227K.
Questions
What was Bioadaptives' revenue in the third quarter 2025?
Bioadaptives (BDPT) reported revenue of $5K for the third quarter 2025 (Q3 2025) and +44% from the quarter before.
Source: Bioadaptives 10-Q on SEC EDGAR.